Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2006

View Archived Issues

Crucell looks back on 2005 achievements

AstraZeneca updates Q4 accomplishments

Neuroprotective potential of the HCT PAN-811

Cytogen and Savient sign letter of intent for Soltamox U.S. rights

Orphan drug designation for Ultratrace MIBG

Immune Response to focus on NeuroVax and IR-103

Targeting FXR for hyperglycemia and hyperlipidemia in diabetes

Avexa signs license agreement with MNLpharma for HIV integrase inhibitors

Neose Technologies receives milestone from Novo Nordisk

Nymox updates Alzheimer's programs

Zelos completes enrollment in two phase II studies of Ostabolin-C

Insert submits IND for phase I trials of IT-101

Novartis Ophthalmics to copromote Retisert with Bausch & Lomb

FDA Committee recommends ADHD drug medication guide

Dosing completed in phase IIb study of VLTS-934 in PAD

Recruitment suspended in AVANT trial for safety data review

Isis looks ahead to anticipated milestones of 2006

Progressive weight loss observed in pramlintide dose-ranging study

New MCD inhibitor could be beneficial for ischemic heart disease

Accentia Biopharmaceuticals to launch new combination pain product

New selective nonpeptide CCR8 agonist presented

Recent patents disclose new antiinfective agents

Novel treatments for gastrointestinal disorders described in recent patents

Recent Pfizer patent discloses therapeutic agents for alopecia and acne

Propofol under clinical investigation for the treatment of refractory status epilepticus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.